Cocrystal Pharma (OTCMKTS:COCP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Cocrystal Pharma (OTCMKTS:COCP) announced its earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.02, Bloomberg Earnings reports. The firm had revenue of $0.49 million during the quarter.

Shares of OTCMKTS COCP traded up $0.05 during mid-day trading on Wednesday, reaching $0.51. The company had a trading volume of 60,862 shares, compared to its average volume of 28,566. The business’s 50-day moving average is $1.37 and its 200-day moving average is $2.07. Cocrystal Pharma has a 52 week low of $0.45 and a 52 week high of $5.28.

About Cocrystal Pharma

Cocrystal Pharma, Inc, formerly Biozone Pharmaceuticals, Inc, is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.

Featured Article: Marijuana Stocks

Earnings History for Cocrystal Pharma (OTCMKTS:COCP)

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with's FREE daily email newsletter.